Viyash Scientific Limited (VIYASH.NS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | INR bn | 12 | 14 | 14 | 14 | 14 | 16 | 34 | 31 |
| Operating profit | INR bn | 4 | 4 | ||||||
| Net profit | INR bn | 1 | 1 | 0 | -1 | -0 | 0 | 2 | 2 |
| EPS reported | INR | 4.01 | 4.09 | ||||||
| Operating cashflow per share | INR | 6.09 | 1.03 | ||||||
| Capex per share | INR | 3.11 | 0.37 | ||||||
| FCF per share | INR | 2.98 | 0.66 | ||||||
| Free cash flow | INR bn | 1 | 0 | ||||||
| Net debt | INR bn | 2 | 2 | ||||||
| Book value equity | INR bn | 29 | 29 | ||||||
| Book value per share | INR | 65.85 | 64.97 | ||||||
| Number of shares | m | 442.1 | 448.1 | ||||||
| DPS (TTM paid) | INR | - | 0.00 |
Financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 35.15 | 65.00 | ||||||
| P/B LTM | x | 2.72 | 1.20 | ||||||
| P/S LTM | x | 3.06 | 1.11 | ||||||
| P/FCF LTM | x | 61.41 | 121.39 | ||||||
| EV/EBITDA LTM | x | 26.92 | 6.70 | ||||||
| EV/Sales LTM | x | 2.38 | 3.89 | ||||||
| Earnings Yield LTM | % | +2.19% | +1.54% | ||||||
| FCF Yield | % | +1.63% | +0.82% | ||||||
| Quality | |||||||||
| ROE | % | - | +12.73% | ||||||
| ROIC | % | +7.07% | +6.68% | ||||||
| Operating margin | % | +12.30% | +12.85% | ||||||
| Gross margin | % | +30.95% | +33.88% | ||||||
| FCF/Sales | % | +3.77% | +0.91% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +371.76% | - | ||||||
| Sales Growth YoY | % | +120.47% | +130.46% | ||||||
| Net Income Growth YoY | % | +710.24% | - | ||||||
| FCF Growth | % | +191.48% | - | ||||||
| Operating Profit Growth | % | -8.25% | +992.95% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | - | 0.00% | ||||||
| FCF/Debt | x | 0.26 | 0.06 | ||||||
| Net Debt/EBITDA | x | 0.34 | 0.38 | ||||||
| EBIT/Net interest | x | 6.08 | 7.06 | ||||||
| Net debt/market cap | % | +5.70% | +3.75% | ||||||
| Net debt/Equity | x | 0.06 | 0.08 | ||||||
| Gross debt/equity | x | 0.17 | 0.17 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Viyash Scientific Limited is a global veterinary healthcare company with operations spanning Europe, Asia, and other international markets. It specializes in developing and supplying finished dosage forms for a range of therapeutic applications, including nutritional support, pain relief, parasite control, antibiotic treatments, and gut health solutions. These products cater to various animals like livestock, poultry, and domestic pets. Additionally, the company extends its expertise through analytical testing and specialized veterinary formulation services. Originally established as Sequent Scientific Limited, the company officially adopted the name Viyash Scientific Limited in January 2026. Founded in 1985, its corporate headquarters are situated in Hyderabad, India. Currently, Viyash Scientific Limited functions as a subsidiary of CA Harbor Investments.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Viyash Scientific Limited (VIYASH.NS)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Viyash Scientific Limited is a global veterinary healthcare company with operations spanning Europe, Asia, and other international markets. It specializes in developing and supplying finished dosage forms for a range of therapeutic applications, including nutritional support, pain relief, parasite control, antibiotic treatments, and gut health solutions. These products cater to various animals like livestock, poultry, and domestic pets. Additionally, the company extends its expertise through analytical testing and specialized veterinary formulation services. Originally established as Sequent Scientific Limited, the company officially adopted the name Viyash Scientific Limited in January 2026. Founded in 1985, its corporate headquarters are situated in Hyderabad, India. Currently, Viyash Scientific Limited functions as a subsidiary of CA Harbor Investments.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free